Ono Pharmaceutical Co., Ltd.
OPHLYOTCHealthcare● Active
$4.63
+$0.08(+1.76%)
Market Cap$6.5B
P/E Ratio—
52W High$5.75
52W Low$3.35
Ono Pharmaceutical Co., Ltd. (OPHLY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OPHLY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
$0.00
Est. $0.02 · -78.5%
Revenue
$0.76B
Est. $0.72B · +5.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
OPHLY reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.07 | — | — | — | $0.68B | — |
| ▼ Q2 FY2026 | May 8, 2026 | $0.02 | $0.00 | -78.5% | $0.76B | $0.72B | +5.6% |
| ▲ Q1 FY2026 | Feb 2, 2026 | $0.10 | $0.13 | +36.5% | $0.90B | $0.83B | +7.8% |
| ▲ Q4 FY2025 | Oct 29, 2025 | $0.09 | $0.11 | +20.3% | $0.88B | $0.85B | +3.8% |
| ▼ Q3 FY2025 | Jul 29, 2025 | $0.11 | $0.09 | -23.7% | $0.88B | $0.82B | +7.2% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.03 | -$0.03 | -210.3% | $0.77B | $0.82B | -5.5% |
| ▼ Q1 FY2025 | Feb 3, 2025 | $0.09 | $0.07 | -23.5% | $0.87B | $0.85B | +2.6% |
| ▼ Q4 FY2024 | Oct 31, 2024 | $0.11 | $0.08 | -28.4% | $0.82B | $0.84B | -2.3% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.07
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
$0.00
EPS Est.
$0.02
EPS Surpr.
-78.5%
Revenue
$0.76B
Q1 FY2026
Feb 2, 2026Beat
EPS Actual
$0.13
EPS Est.
$0.10
EPS Surpr.
+36.5%
Revenue
$0.90B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$0.11
EPS Est.
$0.09
EPS Surpr.
+20.3%
Revenue
$0.88B
Q3 FY2025
Jul 29, 2025Miss
EPS Actual
$0.09
EPS Est.
$0.11
EPS Surpr.
-23.7%
Revenue
$0.88B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.03
EPS Est.
$0.03
EPS Surpr.
-210.3%
Revenue
$0.77B
Q1 FY2025
Feb 3, 2025Miss
EPS Actual
$0.07
EPS Est.
$0.09
EPS Surpr.
-23.5%
Revenue
$0.87B
Q4 FY2024
Oct 31, 2024Miss
EPS Actual
$0.08
EPS Est.
$0.11
EPS Surpr.
-28.4%
Revenue
$0.82B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $11.37 | $11.85 | $12.35 | 1 |
| Q4 FY2026 | $14.92 | $15.55 | $16.21 | 1 |
| Q3 FY2026 | $11.67 | $12.16 | $12.68 | 1 |
| Q2 FY2026 | $10.93 | $11.39 | $11.88 | 1 |
| Q1 FY2026 | $2.64 | $2.75 | $2.87 | 1 |
| Q4 FY2025 | $14.50 | $15.11 | $15.76 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $113B | $116B | $120B | 1 |
| Q4 FY2026 | $117B | $121B | $125B | 2 |
| Q3 FY2026 | $109B | $112B | $116B | 3 |
| Q2 FY2026 | $104B | $108B | $112B | 3 |
| Q1 FY2026 | $109B | $115B | $120B | 5 |
| Q4 FY2025 | $120B | $131B | $135B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -78.5% | $5.03 | $5.23 | +3.98% |
| ▲ Q1 FY2026 | Feb 2, 2026 | +36.5% | $4.91 | $5.08 | +3.46% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +20.3% | $3.95 | $3.85 | -2.53% |
| ▼ Q3 FY2025 | Jul 29, 2025 | -23.7% | $3.68 | $3.70 | +0.54% |
| ▼ Q2 FY2025 | May 8, 2025 | -210.3% | $3.61 | $3.55 | -1.66% |
| ▼ Q1 FY2025 | Feb 3, 2025 | -23.5% | $3.40 | $3.31 | -2.65% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -28.4% | $4.16 | $4.13 | -0.72% |
| ▼ Q3 FY2024 | Jul 31, 2024 | -4.2% | $4.90 | $4.86 | -0.82% |
Q2 FY2026+3.98%
Report Date
May 8, 2026
EPS Beat/Miss
-78.5%
Price Before
$5.03
Price After
$5.23
Q1 FY2026+3.46%
Report Date
Feb 2, 2026
EPS Beat/Miss
+36.5%
Price Before
$4.91
Price After
$5.08
Q4 FY2025-2.53%
Report Date
Oct 29, 2025
EPS Beat/Miss
+20.3%
Price Before
$3.95
Price After
$3.85
Q3 FY2025+0.54%
Report Date
Jul 29, 2025
EPS Beat/Miss
-23.7%
Price Before
$3.68
Price After
$3.70
Q2 FY2025-1.66%
Report Date
May 8, 2025
EPS Beat/Miss
-210.3%
Price Before
$3.61
Price After
$3.55
Q1 FY2025-2.65%
Report Date
Feb 3, 2025
EPS Beat/Miss
-23.5%
Price Before
$3.40
Price After
$3.31
Q4 FY2024-0.72%
Report Date
Oct 31, 2024
EPS Beat/Miss
-28.4%
Price Before
$4.16
Price After
$4.13
Q3 FY2024-0.82%
Report Date
Jul 31, 2024
EPS Beat/Miss
-4.2%
Price Before
$4.90
Price After
$4.86
Avg Beat Reaction+0.47%
Avg Miss Reaction-0.22%
Beat Rate2 / 8 quarters
Largest Move+3.98% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OPHLY ends December
Ono Pharmaceutical Co., Ltd. (OPHLY) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $0.00 — missing the analyst consensus of $0.02 by -78.5%. The next OPHLY earnings date is expected around September 1, 2026.
Each quarter, investors track OPHLY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OPHLY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OPHLY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OPHLY earnings · 5 questionsOno Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. OPHLY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OPHLY historically reports after market close (AMC).
OPHLY earnings datewhen is OPHLY earningsOPHLY next earnings datewhen does OPHLY report earningsOPHLY earnings calendar
▸ Source: FMP · Ono Pharmaceutical Co., Ltd. SEC filings · US GAAP · Ono Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026